*DJ Elbit Imaging to Sell Up to 25% of Share Capital of Elbit Medical
*DJ Elbit Imaging to Sell Up to 25% of Share Capital of Elbit Medical
Press Release: ELBIT IMAGING ANNOUNCES THE SIGNING OF AN AGREEMENT FOR THE SALE OF UP TO 25% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.
新聞稿：埃爾比特影像宣佈簽署出售埃爾比特醫療有限公司最多25%股本的協議
ELBIT IMAGING ANNOUNCES THE SIGNING OF AN AGREEMENT FOR THE SALE OF UP TO 25% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.
埃爾比特影像公司宣佈簽署一項協議，出售埃爾比特醫療有限公司最多25%的股本。
Tel Aviv, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that it has signed a Share Purchase Agreement ("SPA") with an SPV related to the Exigent Capital Group ("SPV") for the sale of between 3,760,417 ordinary shares of Elbit Medical Technologies Ltd. ("Elbit Medical") (1.6% of its outstanding share capital) and 57,968,760 ordinary shares of Elbit Medical (25% of its outstanding share capital) (the "Maximum Quantity").
以色列特拉維夫，2019年2月7日(環球網)--埃爾比特成像有限公司(TASE，NASDAQ：EMITF)(以下簡稱“埃爾比特”或“本公司”)今天宣佈，它已與與Exigent Capital Group(“SPV”)有關的一家特殊目的機構簽署了一項股份購買協議(SPA)，出售埃爾比特醫療技術有限公司(“Elbit Medical”)的3,760,417股普通股(佔其流通股的1.6%)。
Under the terms of the SPA, the SPV is to purchase an aggregate number of between 3,760,417 and 28,984,380 shares of Elbit Medical for a price per share of NIS 0.96 ($0.26 based on the NIS-US$ representative rate of exchange as of today) on or before March 18, 2019 (the "Initial Closing").
根據SPA的條款，SPV將在2019年3月18日或之前以每股0.96新謝克爾(根據今天的新謝克爾-美元代表性匯率)的價格購買總計3,760,417股至28,984,380股Elbit Medical股票。
During the period from the Initial Closing until May 13, 2019, the SPV may purchase additional shares up to the Maximum Quantity (including the shares purchased at the Initial Closing), for a price per share of NIS 1.02 ($0.28 based on the NIS-US$ representative rate of exchange as of today) ("Per Share Price"), but it is not obligated to do so.
在初始成交至2019年5月13日期間，SPV可以以每股1.02新謝克爾(以今天的NIS-美元代表匯率計算為0.28美元)的價格購買不超過最大數量的額外股票(包括在初始成交時購買的股票)(“每股價格”)，但沒有義務這樣做。在此期間，SPV可以購買不超過最大數量的額外股票(包括在初始成交時購買的股票)，每股價格為1.02新謝克爾(根據今天的新謝克爾-美元代表性匯率計算為0.28美元)，但沒有義務這樣做。
If, prior to May 13, 2019, the Company receives a binding, irrevocable offer from a third party to acquire Elbit Medical shares for a price per share (the "Offer Price") at least 7.5% higher than the Per Share Price, then the SPV shall have the right of first refusal ("Right of First Refusal").
如果在2019年5月13日之前，本公司收到第三方提出的具有約束力的、不可撤銷的要約，以每股價格(“要約價”)至少比每股價格高出7.5%的價格收購Elbit Medical股票，則SPV擁有優先購買權(“優先購買權”)。
In addition, in such event, the SPV shall have the right to tag-along with such sale of shares to the offeror. In the event that the SPV does not exercise its Right of First Refusal, the SPV shall be entitled to compensation as specified in the SPV.
此外，在這種情況下，SPV有權在向要約人出售股份的同時貼上標籤。特殊目的機構不行使優先購買權的，有權獲得特殊目的機構規定的賠償。
As previously disclosed, under a previous Share Purchase Agreement, dated August 7, 2018 (the "Previous SPA"), the Company has sold to entities related to Exigent Capital Group a total of 60,087,537 shares of Elbit Medical, constituting approximately 26% of the Elbit Medical's issued and outstanding share capital.
如先前所披露，根據日期為2018年8月7日的先前購股協議(“先前SPA”)，本公司已向Exigent Capital Group相關實體出售合共600,087,537股Elbit Medical股份，佔Elbit Medical已發行及已發行股本約26%。
The parties also amended the three-year voting agreement (that was signed together with the Previous SPA) regarding the appointment of directors in Elbit Medical.
雙方還修改了關於任命埃爾比特醫療公司董事的為期三年的投票協議(與前SPA一起簽署)。
During the term of the amended voting agreement, commencing May 13, 2019, each party shall have a right of first offer with respect to any sale of shares by the other party, subject to certain exceptions.
在修改後的投票協議期限內，從2019年5月13日開始，除某些例外情況外，每一方都有權就另一方的任何股份出售提出第一要約。
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects, " "anticipates," "projects," "predicts," "estimates," "aims," "believes, " "hopes," "potential" or similar words and includes relating to the possibility of completing the transaction with the SPV. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those projected, expressed or implied in the forward-looking statements. Such risks and uncertainties include, without limitation, the risk that the SPV will be unable to complete the transaction and purchase Elbit Medical shares. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 27, 2018. Any forward-looking statements contained in this press release speaks only as of the date of this press release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in this press release will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
本新聞稿包含1995年“私人證券訴訟改革法”所指的“前瞻性陳述”。此類聲明的前綴可以是“打算”、“可能”、“將會”、“計劃”、“預期”、“預期”、“項目”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語，包括與完成與SPV的交易的可能性有關的詞語。前瞻性陳述基於某些假設，會受到各種已知和未知的風險和不確定因素的影響，其中許多風險和不確定因素是公司無法控制的，無法預測或量化，因此，實際結果可能與前瞻性陳述中預測、表達或暗示的結果大不相同。此類風險和不確定性包括但不限於SPV無法完成交易和購買Elbit Medical股票的風險。有關公司的更詳細信息以及可能影響前瞻性陳述實現的風險因素，請參閲公司提交給美國證券交易委員會(SEC)的文件，包括公司於2018年4月27日提交給證券交易委員會的Form 20-F年度報告。本新聞稿中包含的任何前瞻性陳述僅代表截至本新聞稿發佈之日的情況，我們告誡現有投資者和潛在投資者不要過度依賴此類陳述。此類前瞻性陳述並不聲稱是對未來事件或情況的預測，因此，不能保證本新聞稿中包含的任何前瞻性陳述都將被證明是準確的。我們沒有義務更新或修改任何前瞻性陳述。
About Elbit Imaging Ltd.
關於埃爾比特成像有限公司
Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; and (ii) land in India which is designated for sale (and which was initially designated for residential projects).
埃爾比特成像有限公司經營以下主要業務領域：(I)通過我們在InSightec有限公司和Gamida Cell有限公司的間接持股經營醫療行業；以及(Ii)指定出售的印度土地(最初指定用於住宅項目)。
For Further Information:
欲瞭解更多信息，請訪問：
Company Contact
Ron Hadassi
CEO and Chairman of the Board
of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
-----------------------------
公司聯繫人羅恩·哈達西首席執行官兼董事會主席董事中的一員電話：+972-3-608-6048傳真：+972-3-608-6050郵箱：ron@elbitimaging.com-----------------------------
(END) Dow Jones Newswires
(完)道瓊通訊社
February 07, 2019 16:08 ET (21:08 GMT)
2019年02月07日東部時間16：08(格林尼治標準時間21：08)
*DJ Elbit Imaging to Sell Up to 25% of Share Capital of Elbit Medical
*DJ Elbit Image將出售Elbit Medical最多25%的股本
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
(更多信息)道瓊斯通訊社(212-416-2800)
February 07, 2019 16:25 ET (21:25 GMT)
2019年2月7日美國東部時間16：25(格林尼治標準時間21：25)
Copyright (c) 2019 Dow Jones & Company, Inc.
版權所有(C)2019年道瓊斯公司。
譯文內容由第三人軟體翻譯。